Elanco Animal Health Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 6, 2026 results vs estimates
Elanco Animal Health Forecast
Elanco Animal Health short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 27.0% a year, a typical one-standard-deviation range is 22.36–24.12 over a week, 21.43–25.05 over a month and 16.97–29.51 over a year. (Signals as of 1 Nov 2026.)
Elanco Animal Health Price Chart
Elanco Animal Health Factors
YoY −5.0%
YoY +8.4%
YoY +35.2%
YoY −8.1%
YoY +5.8%
YoY −483.4%
YoY +6.5%
YoY −7.9%
YoY +20.9%
YoY −13.1%
YoY −13.0%
YoY −34.7%
YoY −6.2%
YoY −28.6%
YoY +6.4%
Elanco Animal Health fundamentals: income statement, balance sheet & cash flow
Elanco Animal Health reported revenue of $4.72bn and net income of -$232.0m in FY2025, the year ended 31 December 2025 — revenue up 6.2% and net income down 168.6% on the prior year. Free cash flow was $284.0m. These figures are as reported in the filings, not restated: 11 fiscal years and 40 quarters of history, back to December 2015. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 4,715.0 | 4,439.0 | 4,417.0 | 4,411.0 | 4,764.0 |
| Cost of revenue | 2,665.0 | 2,530.0 | 2,479.0 | 2,441.0 | 2,688.0 |
| Gross profit | 2,050.0 | 1,909.0 | 1,938.0 | 1,970.0 | 2,076.0 |
| Research & development | 368.0 | 344.0 | 327.0 | 321.0 | 369.0 |
| Selling, general & admin. | 1,430.0 | — | — | — | — |
| Operating income | 252.0 | 251.0 | 326.0 | 384.0 | 304.0 |
| EBITDA | 676.0 | 1,489.0 | -224.0 | 866.0 | 409.0 |
| Interest expense | 220.0 | 339.0 | 277.0 | 256.0 | 264.0 |
| Pre-tax income | -224.0 | 488.0 | -1,195.0 | -72.0 | -571.0 |
| Income tax | 8.0 | 150.0 | 36.0 | 6.0 | -88.0 |
| Net income | -232.0 | 338.0 | -1,231.0 | -78.0 | -483.0 |
Download Elanco Animal Health fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ELAN.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Elanco Animal Health
Explore MacroFinance macro & markets research and analysis.
Elanco Animal Health Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Elanco Animal Health; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Elanco Animal Health’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Elanco Animal Health (United States)
Elanco Animal Health is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Elanco Animal Health?
What is the latest Elanco Animal Health price?
Is Elanco Animal Health in an uptrend?
How volatile is Elanco Animal Health?
What factors affect Elanco Animal Health?
Which trading strategies trade Elanco Animal Health?
How are Elanco Animal Health returns analysed?
Where can I download free Elanco Animal Health historical data?
Free Elanco Animal Health historical data (last 10 years)
Browse or instantly download the last 10 years of Elanco Animal Health daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ELAN.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 25.74 |
| 2026-11-19 | 26.29 |
| 2026-11-18 | 26.7 |
| 2026-11-17 | 25.85 |
| 2026-11-16 | 26.41 |
| 2026-11-13 | 26.78 |
| 2026-11-12 | 26.5 |
| 2026-11-11 | 26.48 |
| 2026-11-10 | 26.76 |
| 2026-11-09 | 26.84 |
About this stock
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.